newsfilter
← Latest News
GlobeNewswire·

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results

Fourth-quarter and full-year 2025 Rezdiffra® (resmetirom) net sales of $321.1 million and $958.4 million, respectively As of year-end 2025, more than 36,250 patients on Rezdiffra Built industry-leading MASH pipeline